← Back to Search
Antiinflammatory Therapy For Dry Eye.
Published 2004 · Medicine
Download PDFAnalyze on Scholarcy
PURPOSE To present evidence establishing the relationship between inflammation and dry eye and supporting the use of antiinflammatory therapy for dry eye. DESIGN Analysis of literature. METHODS Research studies that evaluated inflammation in dry eye pathogenesis and clinical trials of antiinflammatory therapies for dry eye were reviewed. RESULTS There is increasing evidence that decreased tear secretion, decreased tear turnover, and desiccation promote inflammation on the ocular surface. An increase in soluble mediators (cytokines and proteases) in the tear fluid, adhesion molecule expression by the conjunctival epithelium, and T-cell infiltration of the conjunctiva have been observed in dry eye patients. This inflammation appears to have a role in the pathogenesis of the ocular surface epithelial disease, termed keratoconjunctivitis sicca (KCS), that develops in dry eye. Clinical improvement of KCS has been observed after therapy with antiinflammatory agents including corticosteroids, cyclosporin and doxycycline. Cyclosporin A emulsion was approved by the Food and Drug Administration as therapy for dry eye. Randomized placebo-controlled FDA clinical trials showed that cyclosporine A was superior to vehicle in stimulating aqueous tear production, decreasing corneal punctuate fluorescein staining, reducing symptoms of blurred vision, and decreasing artificial tear use in patients with KCS. No ocular or systemic toxicity was observed from this medication. CONCLUSIONS Ocular surface and lacrimal gland inflammation has been identified in dry eye that plays a role in the pathogenesis of KCS. Antiinflammatory therapy has efficacy for treating KCS. Cyclosporin A is the first FDA approved therapy for this indication. It improved signs and symptoms of KCS, and it is safe for long-term use.
This paper references
Mechanisms of action of cyclosporine.
S. Matsuda (2000)
Interleukin-6 Levels in the Conjunctival Epithelium of Patients with Dry Eye Disease Treated with Cyclosporine Ophthalmic Emulsion
K. Turner (2000)
Effects of Matrix Metalloproteinase-9 Gene Knock-Out on the Proteolysis of Blood–Brain Barrier and White Matter Components after Cerebral Ischemia
M. Asahi (2001)
Evaluation of Subjective Assessments and Objective Diagnostic Tests for Diagnosing Tear‐Film Disorders Known to Cause Ocular Irritation
S. Pflugfelder (1998)
Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren syndrome.
P. Marsh (1999)
Regulation of MMP-9 activity in human tear fluid and corneal epithelial culture supernatant.
L. Sobrin (2000)
Matrix Metalloproteinase-8 Is Expressed in Rheumatoid Synovial Fibroblasts and Endothelial Cells
R. Hanemaaijer (1997)
Regulation of cell death and survival in intestinal intraepithelial lymphocytes
T. Brunner (2001)
Prevalence of dry eye among the elderly.
O. Schein (1997)
A novel mechanism of action of tetracyclines: effects on nitric oxide synthases.
A. Amin (1996)
Molecular aspects of glucocorticoid hormone action in rheumatoid arthritis.
G. Neeck (2002)
Apoptosis of ocular surface cells in experimentally induced dry eye.
S. Yeh (2003)
Glucocorticoid-regulated transcription factors.
I. Adcock (2001)
Non-surgical periodontal therapy with adjunctive topical doxycycline: a double-blind randomized controlled multicenter study.
P. Eickholz (2002)
Effect of methylprednisolone-pulse therapy on superoxide production of neutrophils.
T. Yoshida (1999)
Regulation of MMP-9 production by human corneal epithelial cells.
D. Li (2001)
Rapid Assay of Lactoferrin in Keratoconjunctivitis Sicca
C. J. McCollum (1994)
Flow cytometric analysis of inflammatory markers in conjunctival epithelial cells of patients with dry eyes.
F. Brignole (2000)
The permeability transition pore complex: another view.
A. Halestrap (2002)
Serum and in vitro production of IL-1 receptor antagonist correlate with C-reactive protein levels in newly diagnosed, untreated lupus patients.
L. B. Liou (2001)
Influence of age and sex on flow of tears.
J. Henderson (1950)
Post‐mortem prevalence of lymphocytic infiltration of the lacrymal gland: A comparative study in autoimmune and non‐autoimmune diseases
M. Nasu (1984)
Tear osmolarity--a new gold standard?
R. Farris (1994)
p38 Mitogen‐activated protein kinase and c‐Jun‐NH2‐terminal kinase regulate interleukin‐8 and RANTES production in hyperosmolarity stimulated human bronchial epithelial cells
S. Furuichi (2002)
Negative regulation of nuclear factor-kappaB activation and function by glucocorticoids.
W. Almawi (2002)
Doxycycline inhibition of interleukin-1 in the corneal epithelium
Tear fluid gelatinase B activity correlates with IL-1alpha concentration and fluorescein clearance in ocular rosacea.
A. A. Afonso (1999)
Treatment of recalcitrant recurrent corneal erosions with inhibitors of matrix metalloproteinase-9, doxycycline and corticosteroids.
D. Dursun (2001)
Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjögren's syndrome keratoconjunctivitis sicca.
S. Pflugfelder (1999)
Systemic Diseases Associated with Dry Eye
R. Fox (1994)
Effects of laser in situ keratomileusis on tear production, clearance, and the ocular surface.
L. Battat (2001)
TGF-β increases retinal endothelial cell permeability by increasing MMP-9 : Possible role of glial cells in endothelial barrier function
M. A. Behzadian (2001)
Prevalence of and risk factors for dry eye syndrome.
S. Moss (2000)
Hyperosmolarity Stimulates Production of MMP-9, IL-1ß and TNF- by Human Corneal Epithelial Cells Via a c-Jun NH2-terminal Kinase Pathway
D. Li (2002)
Keratoconjunctivitis sicca and primary Sjögren's syndrome in a Danish population aged 30-60 years.
K. Bjerrum (1997)
Muscarinic acetylcholine receptor antibodies as a new marker of dry eye Sjögren syndrome.
S. Bacman (2001)
Changes in rat corneal matrix metalloproteinases and serine proteinases under vitamin A deficiency.
S. Twining (1997)
Meibomian Gland Dysfunction and Tear Film Abnormalities in Rosacea
N. Zengįn (1995)
[Beneficial effect of the local application of plasma fibronectin and autologous serum in patients with the keratoconjunctivitis sicca of Sjögren's syndrome].
I. Kono (1986)
Pilot Trial of Cyclosporine 1% Ophthalmic Ointment in the Treatment of Keratoconjunctivitis Sicca
R. Laibovitz (1993)
Mononuclear cell phenotypes and immunoglobulin gene rearrangements in lacrimal gland biopsies from patients with Sjögren's syndrome.
J. Pepose (1990)
Differential patterns of response to doxycycline and transforming growth factor beta1 in the down-regulation of collagenases in osteoarthritic and normal human chondrocytes.
B. Shlopov (1999)
Inhalant corticosteroids inhibit hyperosmolarity-induced, and cooling and rewarming-induced interleukin-8 and RANTES production by human bronchial epithelial cells.
S. Hashimoto (2000)
Topical cyclosporin treatment of keratoconjunctivitis sicca in secondary Sjögren's syndrome
K. Gündüz (1994)
Flow cytometric analysis of inflammatory markers in KCS: 6-month treatment with topical cyclosporin A.
F. Brignole (2001)
Assessing the severity of keratitis sicca with videokeratoscopic indices.
C. S. de Paiva (2003)
How matrix metalloproteinases regulate cell behavior.
M. Sternlicht (2001)
Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease.
A. Solomon (2001)
Efficacy and safety of cyclosporin a ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: A dose-ranging, randomized trial☆
D. Stevenson (2000)
Ocular rosacea: patient characteristics and follow-up.
E. Akpek (1997)
Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease1
K. Sall (2000)
Glucocorticoid Effects on NF-κB Binding in the Transcription of the ICAM-1 Gene☆
J. Lidén (2000)
Critical Roles for Interleukin 1 and Tumor Necrosis Factor α in Antibody-induced Arthritis
H. Ji (2002)
Matrix Metalloproteinase-9 (MMP-9) Knockout Alters the Ocular Surface Response to Experimental Dryness
S. Pflugfelder (2002)
Ultraviolet Light and Osmotic Stress: Activation of the JNK Cascade Through Multiple Growth Factor and Cytokine Receptors
C. Rosette (1996)
Beneficial effect of artificial tears made with autologous serum in patients with keratoconjunctivitis sicca.
R. Fox (1984)
Loteprednol Etabonate 0.5% (Lotemax) versus Vehicle in the Management of Patients with KCS and at Least Moderate Inflammation
S. L. Maskin (2003)
Experimental Dry Eye Induced Expression of Inflammatory Cytokines ( IL-1ß and TNF- ), MMP-9 and Activated MAPK by the Corneal Epithelium
Lihui Luo (2003)
Effective treatment of phlyctenular keratoconjunctivitis with oral tetracycline.
W. Culbertson (1993)
Impact of androgen deficiency on the lipid profiles in human meibomian gland secretions.
B. Sullivan (2002)
Efficacy of doxycycline and tetracycline in ocular rosacea.
J. Fruchtpery (1993)
The effect of punctal occlusion on tear production, tear clearance, and ocular surface sensation in normal subjects.
M. T. Yen (2001)
The epidemiology of dry eye in Melbourne, Australia.
C. McCarty (1998)
Adjunctive benefits of subantimicrobial dose doxycycline in the management of severe, generalized, chronic periodontitis.
M. J. Novak (2002)
Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes.
K. S. Kunert (2000)
The role of apoptosis in the pathogenesis of canine keratoconjunctivitis sicca: the effect of topical Cyclosporin A therapy.
J. Gao (1998)
Influence of gender, sex steroid hormones, and the hypothalamic-pituitary axis on the structure and function of the lacrimal gland.
D. Sullivan (1998)
Effects of topical corticosteroids on inflammatory mediator-induced eicosanoid release by human airway epithelial cells.
M. Aksoy (1999)
Fibrinolysis/proteolysis balance in stable angina pectoris in relation to angiographic findings.
J. Paramo (2001)
Spontaneous canine keratoconjunctivitis sicca. A useful model for human keratoconjunctivitis sicca: treatment with cyclosporine eye drops.
R. Kaswan (1989)
Treatment of dry eye by autologous serum application in Sjögren’s syndrome
K. Tsubota (1999)
Oral tetracycline in the treatment of recurrent corneal erosions
Monique W Hope-Rross (1994)
This paper is referenced by
Differential diagnoses of conjunctivitis for clinical allergist-immunologists.
L. Bielory (2007)
Comparison between two cyclooxygenase inhibitors in an experimental dry eye model in albino rabbits
A. Elshazly (2008)
Choice of Artificial Tear Formulation for Patients With Dry Eye: Where Do We Start?
L. Tong (2012)
Current Opinion in Current Opinion in Dysfunctional Tear Syndrome: Dry Eye Disease and Associated Tear Film Disorders -new Strategies for Diagnosis and Treatment to Obtain Ama Pra Category 1 Credit
Ophthalmology Ophthalmology ()
A clinical study of the efficacy of topical corticosteroids on dry eye
C. Yang (2006)
PDE4 inhibition suppresses IL-17-associated immunity in dry eye disease.
Zahra Sadrai (2012)
Attitudes towards Diagnostic Tests and Therapies for Dry Eye Disease
Joanna E Graham (2009)
Effect of inflammation on lacrimal gland function.
D. Zoukhri (2006)
Apical corneal barrier disruption in experimental murine dry eye is abrogated by methylprednisolone and doxycycline.
C. S. de Paiva (2006)
Self-reported compliance with topical cyclosporine emulsion 0.05% and onset of the effects of increased tear production as assessed through patient surveys.
W. Trattler (2006)
Ocular allergy overview.
L. Bielory (2008)
Patologie del film lacrimale e delle superfici oculari nel cane e nel gatto. Parte 2. Segni clinici, diagnosi e terapia
Federica Maggio (2009)
Agreement of Physician Treatment Practices With the International Task Force Guidelines for Diagnosis and Treatment of Dry Eye Disease
S. Wilson (2007)
A novel water-soluble cyclosporine A prodrug: ocular tolerance and in vivo kinetics.
F. Lallemand (2005)
Safety and efficacy of cyclosporine 0.05% drops versus unpreserved artificial tears in dry‐eye patients having laser in situ keratomileusis
George M Salib (2006)
Stress biomarkers in the tear film
L. Banbury (2009)
Development and characterization of Cyclosporine A loaded nanoparticles for ocular drug delivery: Cellular toxicity, uptake, and kinetic studies.
P. Aksungur (2011)
Lipid-Containing Lubricants for Dry Eye: A Systematic Review
Sze-Yee Lee (2012)
Efficacy and Safety of Topical Chloroquine in Mild to Moderate Dry Eye Disease
J. Titiyal (2019)
Human Genetic Diseases
D. Plaseska-Karanfilska (2011)
An Overview on Dry Eye Treatment: Approaches for Cyclosporin A Delivery
B. Yavuz (2012)
Punctal occlusion is safe and efficient for the treatment of keratoconjunctivitis sicca in patients with ocular GvHD
S. Sabti (2012)
Effect of Korean Red Ginseng supplementation on dry eye syndrome in glaucoma patients – A randomized, double-blind, placebo-controlled study
Hyoung Won Bae (2015)
Cornea/External Disease Panel Members
C. Rapuano (2008)
Corneal epithelial opacity in dysfunctional tear syndrome.
J. Chen (2009)
Comparison of prednisolone acetate and loteprednol etabonate for the treatment of benzalkonium chloride-induced dry eye syndrome in rats.
E. Beyazyıldız (2014)
SELDI-TOF-MS ProteinChip array profiling of tears from patients with dry eye.
F. Grus (2005)
Incidence and management of symptomatic dry eye related to LASIK for myopia, with topical cyclosporine A
A. Kanellopoulos (2019)
Observation of Influence of Cataract Surgery on the Ocular Surface
Y. Park (2016)
The Cornea in Diabetes Mellitus
S. A. Hasan (2010)
Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in the Treatment of Severe Dry Eye Disease: A Multicenter Randomized Trial
A. Leonardi (2016)
Updated Meta-Analysis of Acupuncture for Treating Dry Eye
Jun Ba (2013)See more